Cerebral Palsy

  1. Overview and Epidemiology
  2. Classification and Types
  3. Causes and Risk Factors
  4. Diagnosis and Evaluation
  5. Motor Management
  6. Associated Conditions and Comorbidities
  7. Early Intervention and Neuroprotection
  8. Prognosis, Quality of Life, and Long-Term Outcomes
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview and Epidemiology

Cerebral palsy (CP) describes a group of permanent, non-progressive disorders of movement and posture attributed to disturbances occurring in the developing fetal or infant brain. It is the most common cause of severe physical disability in childhood, affecting approximately 1.5–4 per 1,000 live births and an estimated 764,000 individuals in the United States. Worldwide, approximately 17 million people live with CP.

The name "cerebral palsy" describes a clinical syndrome, not a single disease. Many different brain lesion types, timings, and underlying causes all produce the shared hallmarks of motor dysfunction attributable to a non-progressive brain lesion arising before age 2. The spectrum spans from mild — a child who walks independently and attends regular school with few accommodations — to severe, including quadriplegia with no independent ambulation, epilepsy, intellectual disability, and complex medical needs requiring round-the-clock care.

Prevalence has remained relatively stable over recent decades despite major improvements in neonatal intensive care. This stability reflects a countervailing effect: improved survival of extremely preterm infants (born before 28 weeks gestational age), who carry a 40–100 times higher risk of CP than term infants, offsets gains made in reducing brain injury among survivors. Boys are slightly more commonly affected than girls, at a ratio of approximately 1.3:1.

An important conceptual point: the underlying brain lesion is permanent and non-progressive, but the clinical expression of CP evolves as the child develops. Motor signs in early infancy (often hypotonia) give way to the characteristic spasticity or movement disorder seen in older children. Secondary musculoskeletal consequences — contractures, hip displacement, scoliosis — are progressive even though the primary brain injury is not, and are a major focus of long-term management.

Back to Table of Contents

Classification and Types

CP is classified by motor type and by topography (the distribution of limb involvement). This classification is clinically essential because it guides prognosis, treatment selection, therapy goals, and expectations for families.

By Motor Type

Spastic CP (approximately 80–85% of all CP) is the most common form. It results from upper motor neuron injury — typically to the cerebral cortex or corticospinal tracts. Clinically it presents with spasticity (velocity-dependent increased muscle tone, characterized by a "catch" on rapid stretch and a clasp-knife response), weakness, hyperreflexia, positive Babinski sign, and clonus. Spastic CP is further subclassified by topography.

Dyskinetic CP (approximately 6–10%) involves involuntary, uncontrolled, repetitive or writhing movements and results from injury to the basal ganglia or thalamus. It has two main subtypes:

Ataxic CP (approximately 5%) results from cerebellar or spinocerebellar involvement and presents with disturbed coordination, impaired balance, hypotonia, a wide-based gait, and poor fine motor control. It is frequently associated with brain malformations.

Mixed CP (approximately 6%) combines features of more than one motor type; spastic-dyskinetic is the most common combination.

By Topography (applies primarily to spastic CP)

Gross Motor Function Classification System (GMFCS)

The GMFCS is the gold-standard functional classification system for CP, rating children on a five-level scale based on self-initiated motor abilities emphasizing sitting, walking, and wheeled mobility. First published by Palisano et al. in 1997, it has been validated across ages and cultures and is strongly predictive of adult functional outcomes:

The GMFCS level is remarkably stable over time — the level established by age 2 generally predicts the adult level, though improvements are possible in early childhood with intensive intervention.

Back to Table of Contents

Causes and Risk Factors

CP results from brain injury or abnormal brain development. Causes are categorized by timing. A widely held historical belief that most CP resulted from birth asphyxia has been overturned: Sigmund Freud, paradoxically, correctly proposed in 1897 that intrauterine factors were the primary cause, a view confirmed when electronic fetal monitoring in the 1980s and 1990s failed to reduce CP incidence despite reducing intrapartum asphyxia events. The majority of CP — approximately 70–80% — is of prenatal origin.

Prenatal Causes (~70–80%)

Perinatal Causes (~10–20%)

Postnatal Causes (~10%)

Risk Factors

Major risk factors include: extreme prematurity (greatest single risk factor; 40–100x increased risk before 28 weeks), multiple gestation (twin or higher-order; higher risk of prematurity, twin-to-twin transfusion, and co-twin in utero demise), intrauterine growth restriction, maternal infection or chorioamnionitis, male sex, and socioeconomic disadvantage (associated with reduced access to prenatal care).

Back to Table of Contents

Diagnosis and Evaluation

CP is primarily a clinical diagnosis — no single test confirms it. Until recently, diagnosis was typically delayed until age 2 years or beyond. International guidelines published by Novak and colleagues in 2017 established that early, accurate diagnosis is possible by 3–5 months corrected age in high-risk infants and is both feasible and beneficial, enabling earlier access to intervention during the period of greatest neuroplasticity.

Clinical Features Prompting Evaluation

Standardized Early Assessments

For infants 0–5 months corrected age, two standardized tools have the strongest evidence for early CP detection:

MRI Brain

Recommended for all children with suspected CP. MRI identifies an underlying etiology in approximately 80–90% of cases and guides genetic workup and prognostic counseling. MRI patterns correlate with CP subtype: PVL with periventricular signal change and reduced white matter volume predicts spastic diplegia; basal ganglia and thalamic signal abnormality predicts dyskinetic CP; cortical and subcortical ischemic lesions predict spastic hemiplegia; brain malformations are associated with more global forms of CP. Timing of the MRI (within the first year when myelination changes can be assessed) is important for accuracy.

Genetic Workup

Recommended especially when MRI reveals a brain malformation, when the clinical presentation is atypical, or when there is no clear etiology from history and imaging. Chromosomal microarray is the standard first-tier investigation; clinical exome or genome sequencing is increasingly used in malformation-associated CP and has a diagnostic yield of 20–30%.

Additional Investigations

Back to Table of Contents

Motor Management

Motor management is the cornerstone of CP care. The goals are to optimize functional ability, prevent secondary musculoskeletal complications (contractures, hip dislocation, scoliosis), minimize pain, and maximize participation in daily life and community activities. Management is lifelong and requires regular reassessment as the child grows.

Physical and Occupational Therapy

Lifelong goal-directed physiotherapy and occupational therapy form the foundation of motor management. Evidence strongly supports goal-directed functional therapy — where the child and family set meaningful functional goals and therapy works systematically toward them — over impairment-focused exercise alone. Constraint-Induced Movement Therapy (CIMT) for hemiplegic CP involves intensive restraint of the unaffected arm to force practice with the affected limb; multiple randomized trials confirm improvements in affected-hand function. Intensive bimanual training (Hand-Arm Bimanual Intensive Training, HABIT) is an equally effective and often more family-acceptable alternative. Task-specific practice in real environments is superior to decontextualized exercise.

Spasticity Management

Spasticity treatment aims to improve function, reduce pain, facilitate care, and prevent fixed contractures. Treatments are used in combination and selected based on whether spasticity is focal or generalized:

Orthopedic Management

Back to Table of Contents

Associated Conditions and Comorbidities

CP is rarely a motor problem in isolation. In many individuals — particularly those with more severe CP — the management of associated conditions has a greater impact on daily quality of life than motor treatment itself. Recognition and systematic management of comorbidities is an essential component of comprehensive CP care.

Epilepsy

Approximately 30–40% of individuals with CP have epilepsy (highest in spastic quadriplegia, approximately 50–60%; lowest in spastic diplegia, approximately 20%). Seizures often begin in infancy and may be difficult to control — drug-resistant epilepsy is more common in CP than in idiopathic epilepsy. Seizure type varies: infantile spasms, focal seizures, and generalized tonic-clonic seizures all occur. Careful EEG assessment and antiepileptic drug management are required; some children are candidates for epilepsy surgery.

Intellectual Disability

Approximately 50% of individuals with CP have intellectual disability ranging from mild to profound. Crucially, intellectual ability does not correlate simply with motor severity: some children with severe quadriplegia have near-normal cognitive function, while some with mild hemiplegia have significant cognitive impairment. Accurate cognitive assessment requires tools adapted for motor and communication difficulties; standard IQ tests requiring spoken or written responses underestimate ability in many children with CP.

Communication Impairments

Approximately 25–40% of individuals with CP have speech impairments. Dysarthria — a motor speech disorder — is common; it causes slurred, reduced-intelligibility speech from the same muscle weakness and spasticity that affects limbs. Children who are non-verbal or minimally verbal benefit substantially from augmentative and alternative communication (AAC) — from simple picture boards to sophisticated voice-output devices and eye-gaze technology — which can transform educational and social participation.

Pain

Chronic pain is among the most underrecognized and undertreated problems in CP. Approximately 75% of individuals with CP report chronic pain, arising from musculoskeletal sources (hip dislocation, scoliosis, contractures, joint degeneration), spasticity-related muscle spasms, dystonic posturing, gastrointestinal causes, and procedural pain. Pain assessment requires tools adapted for children with communication impairments. Pain management is a central quality-of-life issue and should be systematically addressed in every clinical encounter.

Feeding and Swallowing

Dysphagia affects 50–85% of those with severe CP. Impaired swallowing coordination creates risk of aspiration — silent in many individuals — and resultant aspiration pneumonia is a leading cause of mortality. Videofluoroscopic swallow study (VFSS) objectively characterizes swallowing function and guides texture/consistency modifications. Children with insufficient oral intake for growth or with significant aspiration risk are candidates for gastrostomy tube (G-tube) feeding, which also simplifies medication administration. Oromotor therapy supports development of safer swallowing skills in less severely affected individuals.

Gastrointestinal Complications

Constipation is nearly universal in individuals with GMFCS IV–V CP, driven by dysmotility, reduced physical activity, inadequate fluid and fiber intake, and the constipating effects of medications such as baclofen and antiepileptic drugs. Gastroesophageal reflux disease (GERD) is also highly prevalent. Drooling affects approximately 30% and can be managed with glycopyrrolate (oral anticholinergic) or botulinum toxin injections into the parotid and submandibular salivary glands.

Vision

Strabismus (25–50%) and cortical visual impairment (CVI) — a vision deficit arising from damage to the visual cortex or visual processing pathways rather than the eye itself — are the most common visual disorders in CP. CVI is the leading cause of visual impairment in children in developed countries, and CP is its most common underlying cause. Standard visual acuity testing may underestimate the degree of CVI; specialized CVI assessment and educational interventions are needed.

Sleep Disorders

Sleep disorders affect 40–60% of children with CP, including insomnia, sleep-disordered breathing (obstructive sleep apnea from hypotonia and oromotor dysfunction), and nocturnal dystonia or spasms. Poor sleep exacerbates daytime behavior, cognitive function, and caregiver burden; formal sleep evaluation is underutilized in CP.

Mental Health

Anxiety disorders, depression, and behavioral difficulties are significantly more prevalent in children and adults with CP than in the general population. In children, ADHD comorbidity is common. In adolescents and adults, the challenges of navigating a disability in a society not fully designed for inclusion — including social isolation, educational barriers, and employment discrimination — contribute to mental health burden. Mental health conditions in CP are substantially undertreated.

Back to Table of Contents

Early Intervention and Neuroprotection

The management of CP now begins before or immediately after birth for infants at high risk. Several interventions have evidence for reducing the incidence or severity of CP in at-risk populations, and early therapeutic intervention in diagnosed CP takes advantage of a critical window of neuroplasticity.

Therapeutic Hypothermia (Whole-Body Cooling) for HIE

Therapeutic hypothermia — reducing core body temperature to 33–34°C for 72 hours, initiated within 6 hours of birth — is standard of care for term and near-term newborns (≥36 weeks gestational age) with moderate-to-severe HIE. A meta-analysis of randomized trials by Shankaran and colleagues demonstrated a 25% relative reduction in death or major neurodevelopmental disability. The mechanism involves interrupting the secondary neuronal injury phase (programmed cell death, glutamate excitotoxicity, mitochondrial dysfunction) that follows the initial ischemic insult during the reperfusion period. Therapeutic hypothermia is available in level III and IV NICUs and has substantially changed outcomes for term infants with birth asphyxia.

Antenatal Neuroprotection for Preterm Infants

Early Intervention in Infants Already Diagnosed with or at High Risk for CP

Intrapartum Prevention

It is important to note that universal electronic fetal monitoring — widely expected to reduce CP by preventing intrapartum asphyxia — has not reduced CP rates in any studied population. This failure reinforced the evidence that most CP originates prenatally and cannot be prevented by intrapartum surveillance. Group B Streptococcus screening and intrapartum antibiotic prophylaxis are effective for reducing the subset of CP caused by neonatal GBS meningitis.

Back to Table of Contents

Prognosis, Quality of Life, and Long-Term Outcomes

Predicting Ambulation

The question most parents ask first after a CP diagnosis is whether their child will walk. The GMFCS level established by age 2 years is the strongest predictor of adult GMFCS level — functional ability is largely determined by school age. A practical clinical rule: a child who sits independently without support by age 2 years will, in most cases, eventually walk. A child who is not sitting by age 4 is unlikely to achieve independent ambulation. GMFCS levels show modest improvement in Levels II–III during early childhood with intensive intervention, but large changes across levels are uncommon.

Education

Approximately 50% of children with CP attend regular classes without additional support; many others succeed in inclusive settings with appropriate accommodations, assistive technology, and educational support. Assistive technology is transformative: powered wheelchairs provide independent mobility from as young as 18 months; AAC devices enable academic participation for non-verbal students; eye-gaze and switch-access interfaces allow children with severe motor limitations to engage with curricula and communicate at grade level.

Employment and Adult Life

Adults with CP report employment rates of 25–50%, substantially below population averages, though this varies considerably by GMFCS level, cognitive ability, and communication function. Remote work opportunities and advancing accessibility technology are slowly expanding employment possibilities. The transition from pediatric to adult healthcare services is a recognized crisis point — adult physicians are often unfamiliar with CP management, specialized CP adult clinics are scarce, and many individuals experience deteriorating care at the transition.

Quality of Life — A Critical Corrective Finding

One of the most clinically important findings in CP research is the poor correlation between objective functional severity and subjective quality of life. Multiple large studies show that self-reported quality of life among adults with CP — including those with severe motor impairment — is comparable to the general population on most domains. Pain and social participation are the strongest predictors of QOL, not ambulation status or GMFCS level. This finding powerfully challenges the assumptions clinicians and parents often make about life quality for those with severe motor impairment, and has significant implications for how clinicians counsel families at the time of diagnosis and throughout childhood.

Health in Adulthood

Adults with CP face increased health burdens compared to the general population: chronic musculoskeletal pain (the most prevalent problem), fatigue (often disproportionate to activity level), accelerated musculoskeletal aging with early arthritis and overuse injuries from abnormal gait biomechanics, and mental health challenges. Secondary health deterioration beginning in the 30s and 40s is increasingly recognized, particularly in ambulatory individuals who may have been relatively independent for decades before encountering significant functional decline.

Life Expectancy

GMFCS Levels I–III: near-normal life expectancy in individuals without severe swallowing dysfunction or recurrent respiratory complications. GMFCS Levels IV–V: reduced life expectancy, with aspiration pneumonia as the leading cause of premature mortality. Modern intensive care and proactive respiratory management have substantially improved survival even in the most severely affected individuals; current cohorts are living substantially longer than historical data would predict.

Back to Table of Contents

Key Research Papers

  1. Rosenbaum P et al., 2007 — A report: the definition and classification of cerebral palsy — Developmental Medicine & Child Neurology — PMID: 17370477 — The international consensus definition of CP and its classification; foundational reference for all subsequent epidemiological and clinical work.
  2. Novak I et al., 2013 — A systematic review of interventions for children with cerebral palsy — Developmental Medicine & Child Neurology — PMID: 23692155 — Comprehensive systematic review grading the evidence for all CP interventions using traffic-light coding; essential clinical reference identifying which treatments have strong evidence, weak evidence, or evidence of harm.
  3. Shankaran S et al., 2012 — Childhood outcomes after hypothermia for neonatal encephalopathy — New England Journal of Medicine — PMID: 22913687 — Follow-up of the NICHD whole-body cooling trial demonstrating sustained reduction in death or major disability at 6–7 years of age; established long-term benefit of therapeutic hypothermia for HIE.
  4. Hadders-Algra M, 2022 — Early diagnosis of cerebral palsy and prediction of functional outcome using general movement assessment — Developmental Medicine & Child Neurology — PMID: 35043367 — Review of the GMA evidence base; establishes absent fidgety movements as the highest-sensitivity early marker for CP and outlines its role in NICU follow-up programs.
  5. MacLennan AH et al., 2015 — Cerebral palsy: causes, pathways, and the role of genetic variants — American Journal of Obstetrics and Gynecology — PMID: 25534272 — Reviews the etiological framework of CP including genetic contributions; challenges the birth asphyxia paradigm and establishes the complexity of causal pathways.
  6. Crowther CA et al., 2003 — Effect of magnesium sulfate given for neonatal neuroprotection before preterm birth — JAMA — PMID: 14519704 — The ACT trial establishing that antenatal magnesium sulfate before 30 weeks reduces cerebral palsy in surviving preterm infants; key evidence that shifted obstetric practice globally.
  7. Smithers-Sheedy H et al., 2014 — What constitutes cerebral palsy in the twenty-first century? — Developmental Medicine & Child Neurology — PMID: 24127826 — Addresses case ascertainment challenges in CP registries and surveillance and the evolving boundaries of what constitutes a CP diagnosis with advancing neuroimaging and genetics.
  8. Rosenbloom L, 1994 — Dyskinetic cerebral palsy and birth asphyxia — Developmental Medicine & Child Neurology — PMID: 8050622 — Distinguishes the specific role of perinatal asphyxia in the dyskinetic CP subtype (basal ganglia/thalamic injury) from the minority role of birth asphyxia in spastic CP overall.
  9. Odding E et al., 2006 — The epidemiology of cerebral palsy: incidence, impairments and risk factors — Disability and Rehabilitation — PMID: 16467053 — Comprehensive epidemiological review covering prevalence, associated impairments, and risk factors across international populations; widely cited reference for CP burden of disease.
  10. Palisano R et al., 1997 — Development and reliability of a system to classify gross motor function in children with cerebral palsy — Developmental Medicine & Child Neurology — PMID: 9183258 — Original publication of the Gross Motor Function Classification System (GMFCS); the foundational tool now used globally for CP classification and prognosis.
  11. Boyd RN et al., 2017 — Impact of early exposure to constraint therapy on outcomes at 1 year (ACROBAT trial) — Developmental Medicine & Child Neurology — Randomized trial of early constraint-induced movement therapy in infants with unilateral CP aged 6–18 months; provides evidence for intensive motor intervention during the early neuroplasticity window.
  12. Graham HK et al., 2016 — Cerebral palsy — Nature Reviews Disease Primers — PMID: 27188686 — Comprehensive expert review covering epidemiology, etiology, pathology, classification, diagnosis, management, and quality of life; the most widely cited modern overview of CP across all aspects of the condition.

Back to Table of Contents

Connections

Back to Table of Contents